97% af 1. linje- patienterne oplevede birvirkninger; de mest almindeligt indberettede bivirkninger hos 1. linje- patienterne forekom sædvanligvis i den første behandlingsuge.
Approximately 97% of first-line patients experienced adverse reactions; the most commonly reported reactions in first line patients usually occurred in the first week of therapy.